drugset / Trial / NCT04693039
Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets
Phase 1
Completed
40 enrolled
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Xuanwu Hospital, Beijing · collab
RandomizedParallel-groupTriple-blindOther
Summary
1. To evaluate the safety and tolerability of Phenlarmide tablets in patients with Parkinson's disease in the early and middle stages. 2. To evaluate the pharmacokinetics of Phenlarmide tablets in patients with Parkinson's disease. 3. To explore the efficacy of Phenlarmide tablets in the treatment of early and mid-term Parkinson's disease.
Timeline
- Start
- 2021-02-23
- Primary completion
- 2021-10-29
- Completion
- 2021-10-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Phenlarmide | Unknown | 150 mg | — |
| Subject | Phenlarmide | Unknown | 300 mg | — |
| Subject | Phenlarmide | Unknown | 600 mg | — |
| Subject | Phenlarmide | Unknown | 900 mg | — |